Onesource Specialty Pharma Limited has informed the Exchange regarding Notice of Postal Ballot
ONESOURCE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Onesource Specialty Pharma Limited (formerly Stelis Biopharma Limited) has issued a postal ballot notice seeking shareholder approval to appoint three Independent Directors, each for a five-year term from February 27, 2025 to February 26, 2030. The three appointees are Ms. Debarati Sen (former CEO & MD of 3M India, currently Group President at HMTX Industries), Dr. Claudio Albrecht (former CEO of STADA AG and Actavis Group, currently a Director at Dr. Reddy's Laboratories), and Mr. Vijay Paul Karwal (Managing Director at CBC Group, Singapore). Each director will receive sitting fees of INR 1,00,000 per board/committee meeting plus an annual commission from FY 2025-26. Voting will be conducted electronically via NSDL from April 26, 2025 to May 25, 2025, with the cut-off date for eligibility being April 18, 2025. Results are expected to be announced by May 27, 2025.
This is a routine governance exercise seeking shareholder ratification for independent directors already appointed by the board. The high-caliber international pharma and consumer industry backgrounds of the appointees may strengthen the company's strategic oversight, but it is unlikely to have a direct material impact on stock price.